Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01739023 · ClinicalTrials.gov registry record · Phase 1
Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI
A Phase 1 study, sponsored by W. Dalton Dietrich.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01739023 is a Phase 1 study that has completed, run by W. Dalton Dietrich. The registered enrollment target is 9 participants.
The verdict
NCT01739023, a Phase 1 study, has completed, sponsored by W. Dalton Dietrich.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of autologous human Schwann cells (ahSC) transplantation in subjects with subacute SCI. For humans with subacute SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of ahSC. In addition spinal cord cavitation may be reduced, and neural sprouting and plasticity may be enhanced via neurotrophic effects.
Interventions
- BIOLOGICAL Autologous Human Schwann Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01739023
The ClinicalTrials.gov registry entry for NCT01739023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W. Dalton Dietrich, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous Human Schwann Cells is the first listed.
NCT01739023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01739023 about?
NCT01739023 is a clinical study titled "Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI". The purpose of this study is to assess the safety of autologous human Schwann cells (ahSC) transplantation in subjects with subacute SCI. For humans with subacute SCI, we hypothesize that axons might show improved function if myelin repair is induced with the implantation of ahSC. In addition spina...
What is the current status of trial NCT01739023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01739023?
The interventions under investigation include: Autologous Human Schwann Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01739023?
This trial is sponsored by W. Dalton Dietrich, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.